CDKN2A and neoplasm: Using an immune-competent model of de novo MPNSTs, developed through the Cas9-mediated inactivation of Nf1 and Cdkn2a, we found that the combination of CDK4/6 and MEK inhibitors uniquely induced transient tumor regression, a phenotype not seen in immune-deficient preclinical models.